enews

Communications and Publications Division (CPD) of the IFCC
Editor: Katherina Psarra, MSc, PhD
IFCC Office, Via C. Farini, 81
20159 Milano, Italy
E-mail: enews@ifcc.org

International Federation of Clinical Chemistry and Laboratory Medicine

N° 10 – October 2022

In this issue

EDITORIAL

Message from the eNews Editor

by Katherina Psarra
eNews Editor

Dear colleagues,

Katherina Psarra, MSc, PhD

Our warmest congratulations from the eNews team to Prof. Tomris Ozben for her election as the new President-Elect

Well, IFCC is 70 years old, but it is so young, so vibrant and full of energy, as you will see in this issue of the eNews.

Our President, Prof. Khosrow Adeli, in his message describes all this activity in the divisions, committees, working groups, task forces of our society. He describes the current IFCC strategic plan and the program of the IFCC General Conference to be held in Brussels at the end of the month. Go through his message to learn everything about it. We will have a generous descriptions, with photos and all the details, in the November issue.

“Smart interconnected minds” is the title of the article by Dr. Bernard Gouget about the 16th BCLM 2022 in Tallinn, Estonia. Not only the so modern and interesting scientific information from the meeting but the general atmosphere of the place and the people are presented. Dr. Gouget is guiding us through the IFCC C-MHBLM and m-technologies under the spotlights in Chicago, IL, U.S.A., as well.

It is the turn for Prof. Rahiv Erasmus the C-PR Chair to be interviewed about the 70 years of IFCC.

The IFCC–Abbott VLP program and an IFCC-PSEP educational visit show the importance of the IFCC contribution in the lab medicine professionals' education all over the world. Very educational for all of us is late Prof. Jean-Paul Chapelle’s life as presented in memoriam in this issue.

I hope I persuaded you again that IFCC may be 70 years old but is more active and younger with every passing year.

Stay tuned to the IFCC, stay tuned to the eNews, dear colleagues!

Katherina Psarra

IFCC President's message – October 2022

IFCC: 70 years of global leadership in laboratory medicine

Prof. Khosrow Adeli
PhD, FCACB, DABCC, FAACC

by Khosrow Adeli
IFCC President

IFCC has reached a major milestone this year, celebrating its 70th anniversary with seven decades of contributions to scientific and educational advances in the field of laboratory medicine around the world. Over the past 70 years, IFCC has undergone drastic transformation to expand its reach around the globe and become a pillar of the laboratory medicine community. Today, IFCC is the largest international organization in the field of laboratory medicine, linking 96 full member societies/countries, 20 affiliate member societies, 6 regional federations, and 52 corporate members worldwide. The organization represents an important facilitator of education and international scientific exchange in the field and is known for its contributions to development of standards in laboratory diagnostics.

The current IFCC strategic plan (2020-2023) aims to continue advancing excellence in laboratory medicine for better healthcare worldwide through four main pillars: 1) directly impacting healthcare and patient outcomes, 2) directly contributing to global lab quality, 3) developing evidence on the value and impact of lab medicine in healthcare, and 4) expanding eLearning/distance learning programs worldwide. Main themes that support these pillars include encouraging and supporting a culture of innovation as well as enhancing functional unit productivity. Several Task Forces have been developed in recent years to tackle these objectives, working diligently toward IFCC's new vision. Alongside Task Forces, IFCC Divisions should also be recognized for their achievements that have not only contributed to the growth of the IFCC organization but have also had significant impact on advancing the science of laboratory medicine and *in vitro* diagnostics around the world. These include the Scientific, Education and Management, Communications and Publications, and Emerging Technologies Divisions. Other great accomplishments in the last few years include the first-ever IFCC virtual conference held in early 2021, which brought together leading experts on a global virtual platform to present the latest advances in COVID-19 diagnostics and therapeutics as well as discuss the critical role of clinical laboratories in the COVID-19 pandemic. IFCC also held the first-ever Annual Town Halls to bring the IFCC community together for the purpose of improving internal communication.

IFCC Officers, Members of Committees and Task Forces, Corporate Members, Special Guests including all past presidents of IFCC as well as Presidents of National Societies and Regional Federations have been invited to celebrate this milestone at the General Conference in Brussels, Belgium, from October 28-31, 2022. A special gala dinner will set the perfect backdrop to celebrate the 70th Anniversary of IFCC, recognizing 70 years of global leadership in laboratory medicine and celebrating our contributions to advancing excellence in laboratory medicine

Article continued on next page

for better healthcare worldwide. Attendees can also look forward to a Symposium on the Central Role of Lab Medicine in Patient Care & Public Health (with expert presentations from AACC, WHO, and others), an Industry Forum on the Future of IVD over the Next Decade, Presentations from Past Presidents and Regional Federation Presidents, as well as Progress Reports from IFCC functional groups.

As we reflect on 70 years, it is important to recognize the many milestones that IFCC has accomplished, of which there are too many to list here. Moving forward, I strongly believe that the future holds considerable promise for the IFCC organization and its family of national societies and corporate members. I would like to thank all of our community members for your dedication and contributions to the IFCC organization over the years, aiding significantly in our progress towards the IFCC vision, which we will most certainly continue for years to come!

Let's come together and celebrate this major momentous achievement for the IFCC Organization at all events and conferences throughout the year and continue this long tradition of global leadership in laboratory medicine and *in vitro* diagnostics.

Cheers, Khosrow ☺

The IFCC is pleased to announce its new President-Elect: Prof. Tomris Ozben

Prof. Tomris Ozben

Prof. Ozben will commence her term in office as President-Elect on January 1st, 2023, until December 31st, 2023, to become President January 2024 - December 2026.

The result of the ballot for the election of the President-Elect, to commence the term of office on January 1st, 2023, was concluded on September 30th, 2022. In summary 77 societies voted (out of 89 having the right to vote), giving preferences as follows:

Prof. Tomris Ozben (Turkish Biochemical Society - TBS) received votes: 45 (58.44%)

Prof. Michael Neumaier (German Society for Clinical Chemistry and Laboratory Medicine – DGKL) received votes: 19 (24.68%)

Prof. Tahir Pillay (South African Association for Clinical Biochemistry and Laboratory Medicine - SAACB) received votes: 13 (16.88%)

Full details of the ballot may be found from the independent company that conducted the ballot: https://secure.electionbuddy.com/results/6QQ8F9Q9YVZT.

According to the results, we are glad to announce that the President-Elect is Prof. Tomris Ozben, to continue her term as President until December 2026.

IFCC congratulates all nominated members and the new President-Elect and wishes her a fruitful and successful term of work for the promotion of Clinical Chemistry and Laboratory Medicine worldwide.

Click here to read a profile of Prof. Ozben.

Call for nominations for IFCC Regional Federation Representatives 2024-2026

The IFCC Nominations Committee is announcing the call for nominations for Regional Federation representative members of the IFCC Executive Board for service from January 1, 2024, to December 31, 2026. Each of the six IFCC Regional Federations (AFCB, AFCC, APFCB, EFLM, COLABIOCLI, and NAFCC), will be represented at the Executive Board by one representative of its Region.

This election is under the responsibility of the IFCC Nominations Committee according to the last version of the IFCC statutes and rules. Any full member society in good standing may nominate an individual to serve in the IFCC Executive Board representing his/her Regional Federation.

In order to be an effective representative for the Regional Federation each elected individual should be a member of the IFCC Executive Committee throughout the three-year period 2024-2026. It is for the Regional Executive Committee/Board to determine how this may be achieved, whilst respecting the right of any IFCC Full Member society to submit a nomination. The candidate should have a thorough knowledge of the functioning of his/her Region and must ensure that he/she is able to work in harmony with the Regional Executive Committee/Board and the IFCC Regional membership.

TIMETABLE:

- **1st September - 30th November 2022**
  The call for nominations for the Regional Representatives will be sent to IFCC Full Member Societies and to the Regional Federation Executive Committees/Boards. The closing date for nominations is 30th November 2022.
- **1st - 31st December 2022**
  The Nominations Committee will consult with the respective Regional Executive Committee/Board to determine the eligibility of each Regional Candidate. The IFCC Office then sets the slate for the candidates for each Region.
- **1st - 31st January 2023**
  Slate of candidates is distributed widely throughout IFCC.
- **1st - 28th February 2023**
  Electronic Ballot - The Electorate will be the IFCC Full Members in each Region. The ballot will take place even if there is only a single nomination. The election will be arranged by the IFCC Office using the independent electronic voting system employed by IFCC. The only exception is the “North American Federation of Clinical Chemistry and Laboratory Medicine-NAFCC”; for this specific case, being only two IFCC Full Members forming NAFCC, confirmation in writing, by both Full Member societies supporting the single valid nominee, will remove the need for electronic voting.
- **By 31st March 2023**
  Announcement of elected Regional Representatives.
- **May 2023**
  The elected EB Members for 2024 – 2026 will be presented at the IFCC Council in Rome.

Call for nominations for the Corporate Representative position within the IFCC EB 2024-2026

The IFCC Nominations Committee is announcing the call for nominations of the Corporate Member Representative for service on the Executive Board (EB) from January 1, 2024, to December 31, 2026.

Corporate Members are important partners for IFCC, making a valuable contribution to its scientific, educational and professional activities. The election of the Corporate Member Representative to the EB is an essential component of the operational and strategic management of the Federation, and its influence in the global field of laboratory medicine.

TIMETABLE FOR THE ELECTION OF THE CORPORATE REPRESENTATIVE:

- **1st September - 30th November 2022:**
  Call for nominations.
- **1st - 31st December 2022:**
  Nominations Committee determines the eligibility of each candidate and sets the slate for the candidates for time in office 2024-2026.
- **1st - 31st January 2023:**
  Slate of candidates is distributed to Corporate Members.
- **1st - 28th February 2023:** Electronic Ballot by Corporate Members.
- **By 31st March 2023:**
  Result communicated to candidates.
- **May 2023:**
  Successful candidate presented to the IFCC Council in Rome.

NOMINATION PROCEDURE:

- **Nominations** must be sent electronically to the IFCC Office (ifcc@ifcc.org) **by 30th November.**
- **Consent from the applicant's employer** (who must be an IFCC Corporate Member in good standing), must also be provided.
- **Nominees are invited to include in the application form** a short position statement.

The IFCC–Abbott VLP Program in the 20th Congress of the Sociedad Chilena de Química Clínica

by Eduardo Aranda
National Representative of Chile to the IFCC

The 20th National Conference of the Sociedad Chilena de Química Clínica was held with the attendance of over 350 participants, at the premises of Hotel Intercontinental in Santiago, on August 18-19, 2022 under IFCC auspices. The conference was a two-day event. The pre conference workshops were held on 17th August. The workshops were on Medical Laboratory Diagnostics on ImmuneDiseases and on Validation, Verification and Evaluation of Qualitative Methods with the active participation of Alba Cecilia Garzón (VLP Professor).

The first day of the congress the scientific program started with a Plenary lecture by Dr. Luis Figueroa (VLP Professor) and Dr. Alba Cecilia Garzon (VLP Professor). At the opening ceremoy, the COLABIOCLI president, Dr. Alvaro Justiniano Grosz gave a plaque to the president of the Sociedad Chilena de Clínica Clínica, Dr. Angélica Lagos for the contribution of the Society to the developmet of clinical laboratory profesionals. The opening presentation was delivered by Prof. Dr Alexis Kelergis, on “The Scientifics Deeds Responsible For Vaccines for COVID 19”.

After the conference, the attendees went over to a cocktail party where the Expolab with more than 21 companies exhibiting their products and services was inaugurated. The 2nd day the scientific program started with two plenary conferences by Dr. Steffen Hërtel and Dr. Natalia Vilor-Tejedor (VLP Professor). A total of 9 plenary conferences and 8 symposia were organized in two parallel sessions and 4 workshops were delivered by diagnostics industries. At the closing ceremony Dr. Alvaro Justiniano Grosz gave a lecture on “Strengthening of clinical laboratory professionals in Latin America: Role of COLABIOCLI”.

L-R: Dr. Alba Cecilia Garzón (VLP Professor), Dr. Leverton Ortiz (Member of the Scientific Committee) and Dr. Luis Figueroa (VLP Professor)

Article continued on next page

Dr. Natalia Vilor-Tejedor (VLP Professor) and
Dr. Carolina Ochoa (Scientific Committee Member)

L-R: Dr. Eduardo Aranda (National Representative to the IFCC),
Dr. Natalia Vilor-Tejedor (VLP Professor) and Dr. Claudio Lobos
(President of the Scientific Committee).

Members of the Scientific and the Organizing Committee
of the 20th Congreso Chileno de Quimica Clinica y Ciencias del Laboratorio, Santiago de Chile

Article continued on next page

Closing ceremony and recognition of the best works: poster and oral presentations

Report for the visit of Dr. Luis Figueroa, Dr. Natalia Vilor-Tejedor and Dr. Alba Cecilia Garzón: activities developed by the VLPs

August 16th, 2022. Dr. Luis Figueroa M. Lecture: "Update of Diabetes, Chronic Kidney Disease and Cardiovascular Disease Guidelines" School of Medical Technology, Universidad Santo Tomas, La Serena

August 18th. Dr. Luis Figueroa M. Plenary lecture: "Updating Diabetes, Renal Disease and Cardiovascular Guidelines: How they apply to the Clinical Laboratory".

August 18th. Symposium: "Chronic Noncommunicable Diseases". Dr. Luis Figueroa M. "Myocardial Infarction: Troponins; which, how, when and why?"

August 18th. Symposium: Quality and Patient Safety. Dr. Luis Figueroa M. "Systematic Evaluation of Results - Notification of Critical Values - Analysis and Monitoring".

August 17th, 2022. Dr. Alba Cecilia Garzón. Workshop "Validation, Verification and Evaluation of Qualitative Methods" held at the Universidad Santo Tomás, Santiago.

Dr. Luis Figueroa (VLP Professor) and Professor Paula Reyes (Universidad Santo Tomás, La Serena)

Article continued on next page

August 18th. Dr. Alba Cecilia Garzón. Plenary Lecture “Clinical Risk: Indispensable Management in Patient Safety”.

August 18th. Symposium: “Risk Management and Biosafety. Dr. Alba Cecilia Garzón. Biosafety culture; more than a program+.

August 19th, 2022. Dr. Natalia Vilor-Tejedor. Plenary lecture: “Biomarkers of Aging”.

August 19th. Symposium: Lifestyles and Healthy Aging. Dr. Natalia Vilor-Tejedor “Evidence from the ALFA study (Alzheimer and Families); Biomarkers of accelerated aging in cognitively healthy people”.

August 19th. Dr. Natalia Vilor-Tejedor met with the group of researchers led by Dr. Carolina Ochoa, Center for Healthy Living, University of Concepción, Chile

Dr. Luis Figueroa (VLP Professor), Universidad Santo Tomás, La Serena

L-R: Professor Edinson López, Professor Alba Cecilia Garzón and Leverton Ortiz (Member of the Scientific Committee)

The IFCC C-MHBLM and m-technologies under the spotlights in Chicago, IL, USA

by Bernard Gouget
Chair, IFCC C-MHBLM

Chicago, in Illinois is the third-largest city in the United States. It is a city with a resilient spirit and inspiring comebacks. Chicago is known for its jaw-dropping architecture, culture with this summer a gorgeous Cezanne exhibition, vibrant music scene, amazing food, and iconic neighborhoods. The American Association is part of the North American Federation of Clinical Chemistry and Lab Medicine (NAFCC), one of the six regional federations of the IFCC. It was very inspiring to attend the 2022 AACC Annual scientific meeting and clinical lab expo after the COVID years. Even if, it is an economic and scientific challenge to come to this must-attend event, it is always a pleasure to meet friends and to connect with the global leaders in cutting edge technologies and other areas of breaking science in lab medicine as well as to meet start up, IVD, IT, medical devices companies. The international lab medicine community returned full force to the Mc Cormick Place center, located on Chicago's magnificent lakefront; the Chicago city's Covid policies this summer made us feel safer in the congress areas.

AACC/IFCC session: James Nichols, Bernard Gouget, Damien Gruson and Frank Desiere on the screen

The IFCC Booth with Silvia Colli-Lanzi, IFCC staff on duty, was at an extremely strategic location, place with space to sit, right at the crossroads of the AACC booth and the areas of the IVD major companies. Prof. Fred S. Apple (United States), winner of the 2020 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics and Prof. Nader Rifai (United States), winner of the 2020 IFCC-Howard Morris Distinguished Clinical Chemist Award received on site their awards due to their absence in Seoul 2022. (See photos)

The C-MHBLM, as the initiative of Prof. James Nichols, was invited to organize for Monday, July 25th, an AACC-IFCC energizing and educational session on: "Transforming Lab Medicine through mobile technologies" which received half-page coverage in Monday's "CLN Daily" by Van Leung Pineda, PhD. James Nichols and Frank Desiere, Roche Diagnostics Int., both IFCC C-MHBLM members, who introduced attendees to the emerging fields of eHealth and m-Health. Damien Gruson, IFCC ETD member

Article continued on next page

and Bernard Gouget were a part of the hybrid panel discussion to share insights, express, and challenge opinions in front of an audience.

One of the impacts of the COVID 19 pandemic was the increase spotlight on digital health world. E-Health, m-Health, telehealth, and telemedicine are used to describe the use of mobile and desktop technology for patient management. These terms are used interchangeably at various times; however, each represents a different aspect of technology and healthcare. Mobile health utilizes mobile devices, such as phones, smart watches or a tablet, to support healthcare practices and public health. With m-Health services, patients are able to log, store, and monitor their health records on their personal mobile devices. These applications are helpful in improving the efficiency of the delivery of healthcare information. M-Health applications can be helpful in research for practitioner and patient use. eHealth consists of a much broader understanding of healthcare practices supported by electronic processes. The technology used improved healthcare practices with eHealth including electronic health records, patient administration systems, lab systems, and other records that cannot be stored within mobile health applications. Telemedicine is solely referring to remote clinical service.

Nader Rifai, at the IFCC Booth

The IFCC Booth in Chicago:
S. Colli-Lanzi, K. Adeli, F. Apple, M. Ferrari

Digital health solutions have the potential to bring about great improvements in the delivery and quality of services in healthcare systems. The future of healthcare requires to be more agile, more evidence-driven, more patient-centered. The last two years, digitalization has served a greater purpose: providing people access to care without putting themselves at risk of contracting COVID-19. The pandemic has led to a significant increase in the demand for remote monitoring and patient engagement solutions. As more people gain access to these services, expectations around waiting room times, admission to care, and convenience of care will change. Also F. Desiere reported on the outcome of the survey organized by the IFCC C-MBLM to prepare health systems for the next step in patient data management and m-health integration.

With the growing value of laboratory medicine in informing clinical decisions, e-Health associated with AI can improve diagnostics

Article continued on next page

through more accurate detection of pathology, better laboratory workflows, and improved decision support, leading to accelerated productivity and ultimately enabling better patient outcomes. Uncovering the full potential of digital medicine and AI implementation requires an interconnected data infrastructure with accurate, readily available, and contextualized data. Digital health depends on interoperability—the ability to electronically share health-related data.

The interconnectivity of the mobile data with traditional data is a major challenge for the medical laboratory. There was a large discussion about the integration of the wearable device data that are not currently integrated in the Electronic Health Record (EHR). EHRs and the ability to exchange health information electronically can help providing higher quality and safer care for patients while creating tangible enhancements. EHRs help to better manage care for patients and provide satisfactory health care by providing accurate, up-to-date, and complete information about patients at the point of care, enabling quick access to patient records for more coordinated, efficient care, reduce medical errors, and provide safer care. EHRs reduce medical errors, and provide safer care and more reliable prescribing. Another potential concern is the fact that health information systems could be hacked. Secured sharing electronic information with patients and other clinicians is essential. It is important to take important steps to protect data stored in the IT systems of the medical labs.

The widespread adoption of digital technologies raises also important ethical issues in health care and public health. Understanding these ethical issues demands a perspective that looks beyond the technology itself. After multiple exchanges with participants connected via their mobile, it was clear that the emergence of a new wave of healthcare innovations based on digital technology is raising great hopes and expectations around the transformation of healthcare systems to provide greater quality, to offer more effective, efficient and more personalized services in the future and ultimately to create a supportive digital health ecosystem.

The attendance of several members of C-MHBLM at the AACC in Chicago was an opportunity to meet at the IFCC booth, a real networking platform for the IFCC community, to take stock of the committee's activities.

In mid-2022, the C MHBLM participated in numerous scientific events to promote m-health, e-health and AI. We were on-line at MedLab Middle East in early February to discuss digitalization, automation, and connectivity. Even circumstances were not too easy for the whole C-MBLM, it was possible to go to Leon de los Aldama (Guanajuato MX) in early April to meet our friends from COLABIOCLI at the XXV Latin American congress of Bioquimica Clinica and present the advances in AI, Big Data and wearable technology. The presence at the IFCC/EFLM EuroMedLab Munich 2022 was essential. The C-MHBLM was invited to organize a debate for / against, about Direct-to-Consumer Laboratory Testing (DTCT). DTCT has the potential for self-empowerment of patients but no regulations safeguard the consumers in DTCT. The same is true for the quality insurance and the lack of medical interpretation of test results poses risks to consumers.

For the following weeks and the end of the year to come, James Nichols will attend the 28th AACC International CPOCT Symposium, Sept. 21-23, 2022 in Montreal, Canada to deliver a plenary lecture on "Opportunities for POCT in Patient-Driven Healthcare". Congress President Anu Tamm was kind enough to invite C-MHBLM members to the XVI Baltic Congress in Laboratory Medicine, September 22-24, 2022 in Tallinn, Estonia to talk about "Smart Lab Medicine in the digital age". The congress will be held at the Tallinn Song Festival Grounds. This sprawling event venue in Kadriorg holds a special place in the hearts of Estonians as the birthplace of the singing revolution. IFCC C-MHBLM and ETD are invited to the joint Meeting of BCLF, GSCC-CB co-organized with the AFCB- EFLM LM4MS Second Conference from October 2nd to 5th, 2022 in Heraklion, Crete, Greece, to initiate discussions on how to make easier the implementation of emerging technologies that are useful for the medical services to refugees and immigrants around the Mediterranean Area. The 44th Annual Conference of the Association of Clinical Biochemists in Ireland (ACBI 2022) will be held mid-October, another opportunity to communicate how is "Working in the Lab (from home)"!

Article continued on next page

Since the creation of C-MHBLM, it has become a tradition to participate in the National Conference of the Association of Clinical Biochemists of India to be held this year in New Delhi from 24th to 26th November 2022, with an interesting pre-conference workshop on "Applied AI research in Laboratory Medicine" organized by Prof. Pradeep Dabla. This one day course consists of a hands-on experience that will take the students on a tour to explore the basic concepts of AI and the current and future applications of AI in healthcare with the goal of learning AI technologies into lab medicine and the clinic safely and ethically.

In 2022, the C-MHBLM has published in various scientific journals: APFCB news, IFCC Newsletter, Biochemia Medica (HR), Annales de Biologie Clinique (FR). At the initiative of D. Gruson, important work is underway on the validation framework and data integration of sensors and mobile health devices: a joint position statement of the IFCC Committee on Mobile Health and Bioengineering in Laboratory Medicine (C-MBHLM) and The Healthcare Information and Management Systems Society (HIMSS). The other work topics of the C-MHBLM include the integration of m-health technologies in telemedicine in the post COVID-19 era; the users' satisfaction about m-health applications; the intention to use them in the context of the chronic diseases; the m-health opportunities in low and middle income countries. A special focus is done on ethics, eHealth and AI applications in lab medicine.

For the General conference in Brussels, a Hybrid C-MBLM meeting is planned and C-MHBLM will also be present at IFCC/EFLM WorldLab Roma 2023. The C-MHBLM's research field with AI, m-health, e-health is one of the most rewarding and inspiring initiatives in laboratory medicine, especially when the aim is to improve the quality of care and to tackle disease. The C-MHBLM members are more determined than ever to persevere in their mission, vigilant and constantly keeping watching, in a spirit of cooperation and teamwork within IFCC for the benefit of all.

French young scientists at the Opening ceremony: (R-L) D. Gruson, David Pekar, IFCC-YS, Guillaume Grzych, IFCC-YS, B. Gouget, Jean Marc Giannoli LABAC President and Jean Pierre Bouilloux, LABAC Treasurer

Snibe Diagnostic

MAGLUMI® X3

Save Your Space without Compromise

* Compatible with Small and Medium-sized Hospitals and Labs

All Balanced and Strong

Small but strong

The throughput is up to 200 tests/hour, and the throughput per unit area is 294 T/h/m². Compatible with all MAGLUMI® reagents with perfect compatibility (166 parameters).

Convenient and efficient

No-pause loading/unloading of reagents/samples/reaction cups without waiting or interrupting tests. Intuitive indicator lights make no need to check reagents and consumables frequently.

Low failure rate and accurate result

The single reaction cup can avoid light pollution and increase cuvette utilization, its integrated packaging can avoid the stuck of the cuvette, cuvette blockage and scratches.

Cost-efficient and intelligent

TEFLON-coated pipetting needle is equipped with independent washing unit to avoid carry-over (Small workload analyzer have higher consumable costs when using disposable Tips).

Excellent performance

The comprehensive advanced design of MAGLUMI® X3 ensures excellent performance, such as the latest intelligent washing technology and bidirectional temperature control measurement.

www.snibe.com | sales@snibe.com

Interview with Dr. Rajiv T Erasmus
Chair, PR Committee/CPD-IFCC

Interviewer: Dr. BQF Maria del Carmen Pasquel
Member, CPR and WG-IANT/RIA/CPD-IFCC

Dr. Rajiv T Erasmus



Dr. Maria del Carmen Pasquel

Interview with Dr. Rajiv T Erasmus, Chair Public Relation Committee (CPR) of the Publications and Communications Division (CPD) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), to commemorate the 70th anniversary of the foundation of IFCC.

Dr. Rajiv T Erasmus, MBBS(Ib), FMC.Path(Nig), FWACP(W.A), FCPath(SA), DABCC (Am Board Certified), DHSM(Natal), FC.Path(ECSA) is:

- **Emeritus Professor Chemical Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town;**
- **Vice-President, College of Pathologists of East, Central and Southern Africa (COPECSA);**
- **President, Africa Federation of Clinical Chemistry (AFCC);**
- **Editor-in-Chief, African Journal of Laboratory Medicine (AJLM);**
- **Chair, PR Committee/CPD-IFCC.**

Dear Dr. Rajiv, in this very special year for the IFCC, our readers want to know your answers to the following four questions.

1. **In your position as Chair of the CPR-CPD/IFCC could you give us a short summary of what is the CPR and its objectives?**

Article continued on next page

The IFCC is the biggest laboratory professionals' organization in the world. Thus, we have a great responsibility to the profession and our clinical colleagues that the highest standards with respect to training and education are maintained. We also believe that we need to advise health organizations with respect to the ideal tests that must be used to diagnose diseases using the best available scientific evidence. In this regard the C-PR plays a critical role in supporting the mandate of the IFCC. Some of the objectives include the following:

Identifying key Public Relations tools that can advertise the contributions and mandates of IFCC and make recommendations to other committees and divisions within the IFCC.

Developing and updating promotional materials that can be distributed through the CPD, on the IFCC organization and activities, as well as the discipline of Clinical Chemistry and Laboratory Medicine for distribution worldwide.

Acting as a link for distribution of IFCC brochures and other promotion material to all laboratory professionals in their country of residence, National Societies, and Regional Federations where it applies.

Assisting IFCC in improving its visibility to all laboratory professionals in their country of residence, their respective National Societies and Regional Federations where it applies.

Acting as IFCC ambassadors by promoting IFCC and the field of Clinical Chemistry and Laboratory Medicine to laboratory professionals in their respective country of residence, their National Societies and Regional Federations where it applies.

Promoting IFCC activities to National Representatives on a regular basis through the use of social media tools (eg WhatsApp/Telegram groups) such that these communications can be effectively communicated to their respective members.

Monitoring how effectively are IFCC communications being shared by the National Representatives with their respective members.

Another key activity of the C-PR has been the development of promotional material which can be used by members to promote the IFCC and its activities to the Laboratory Medicine Community and the general public. A promotional slide set and a number of brochures (in multiple languages) are available for download from the Public Relations Resources Page of the website.

We believe that the Corporate sector is important in complementing the role of the PR Committee in communicating the role and objectives of the IFCC at the grass roots level.

More recently members of the Committee are assisting the IFCC in making the public aware of the critical role of the profession and lab professionals in maintaining public health including other colleagues. Even our clinical colleagues are sometimes ignorant of the critical role lab professionals play in ensuring

Article continued on next page

that laboratory results are of the highest quality and are reliable and available to clinicians.

We have had challenges in ensuring that communication is maintained between the PR Committee. Because of the COVID pandemic the Committee was not able to have face to face meetings that we now realise are as important as ever in ensuring that regular communication is taking place.

Even before COVID pandemic there were challenges in communicating with our members but this became worse as conferences and workshops that were organized on a regular basis and were a source of networking virtually disappeared and left a vacuum in the education of colleagues. Innovations in technology allowed for some gaps to be filled but could not replace the personal interaction that normally used to take place at such gatherings.

2. How have you faced the challenges of meeting the CPR objectives in these times of pandemic?

It has been extremely difficult to meet the objectives of C-PR committee in the last 18 months when no one could travel and there was great fear amongst many of our colleagues. That fear still exists with us. Many meetings were cancelled at great economic loss. Plans were disrupted. Connectivity became critical for our survival and proved to be one of the tools we could use to connect with colleagues. Many meetings and conferences utilised internet. Webinars were organized and there was increased usage of tele messaging but again some worked and some didn't. However in many developing countries this was not possible or too expensive. Power outages also had an impact on connectivity. It also meant that colleagues lost important information. The pandemic magnified the inequality gap that is so evident everywhere.

3. What recommendations would you give laboratory medicine professionals after what they have faced in these times of pandemic?

I want lab professionals to educate their families, distant relatives and social colleagues on what they do and how they are contributing to the health security of the world. It is up to us to define who we are. No one will do it for us. Technology has given us the tools and now we must use them effectively to make everyone realise our key role in protecting the planet. Charity begins at home so let's start from there.

4. Something more that you want to say to our readers?

We believe that the lab professionals are the guardians of the planet. Recent events such as Ebola, MERS and the recent COVID pandemic have all emphasized the key role of lab professionals in the diagnosis and follow up of these infectious diseases that are a threat to human existence. Without lab diagnostics the clinician is in the dark. We all need to educate our clinical colleagues and

Article continued on next page

the public at large about our immense contribution to maintain good health and wellness, contributing through this to the global economy. Our professionals are at the helm of technological innovation. Let us acknowledge and give lab professionals the due credit and accolades they deserve. Together we can preserve and conquer.

On behalf of the PR Committee, we appreciate your time and willingness to conduct This interview and we appreciate your excellent work as chair of this IFCC Committee.

Dr. Rajiv Erasmus presiding over one of the zoom meetings held in 2021

In memoriam: Professor Jean-Paul Chapelle

Professor Jean-Paul Chapelle

Professor Jean-Paul Chapelle was born in the surroundings of Liège, Belgium, on November 6th, 1946. He graduated as a Pharmacist from the University of Liège in 1969 and defended his doctoral thesis in 1976. The same year, he started his career in the Clinical Chemistry Department of the University of Liege led by Professor Heusghem. Jean-Paul Chapelle quickly became involved in the field of myocardial biomarkers and he notably highlighted the role of haptoglobin polymorphism as an independent risk factor for myocardial infarction. He published the results of this finding as first author in the New England Journal of Medicine in 1984. His research career has been very fruitful, notably thanks to his work on creatine kinase isoenzymes, on the very early markers of myocardial infarction, and on troponin I and T, for which he was recognized a key opinion leader. Professor Chapelle has been nominated Head of the Clinical Chemistry Department of the CHU de Liège in 2004 until his retirement in 2012. It was under his leadership that the laboratories of the Department became pioneers in quality management, first by being accredited according to ISO 17025 in 2000, then according to ISO 15189 in 2005.

Professor Chapelle has largely contributed to the transmission of his knowledge in clinical chemistry through the numerous courses in pharmaceutical sciences and biomedical sciences that he has given at the University of Liège. He has also been very active in various national and international scientific societies. He was notably Past-President of the Belgian Society of Clinical Chemistry (which later became the Royal Belgian Society of Laboratory Medicine) and Belgian National Representative to the International Federation of Clinical Chemistry (IFCC) for many years.

Jean-Paul Chapelle was also known among his pairs as a very nice and kind person, a polite and friendly colleague who was always listening, soft spoken but very much to the point. During all the years I have personally been working with him, I will never thank him enough for the confidence and freedom he gave and for his wise advice.

Professor Chapelle passed away on September 26th, 2022, leaving behind his beloved wife and two children who followed his path and successfully pursued a medical career.

Etienne Cavalier
Professor of Clinical Chemistry, University of Liège, CHU de Liège
President of the Royal Belgian Society of Laboratory Medicine

21-25 May

WORLDLAB · EUROMEDLAB
ROMA 2023

25TH INTERNATIONAL CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

25TH EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

55TH CONGRESS OF THE ITALIAN SOCIETY OF CLINICAL BIOCHEMISTRY AND CLINICAL MOLECULAR BIOLOGY

MZ EVENTS

ORGANISING SECRETARIAT
Via Carlo Farini 81 - 20159 Milano (Italy)
Phone: +39 02 66802323
E-mail: info@2023roma.org

IFCC-PSEP educational visit to the Hormone Laboratory at Oslo University Hospital

by Vivek Pant, MD
Samyak Diagnostic Pvt Ltd
Kathmandu, Nepal

I had an opportunity of visiting the hormone laboratory at Oslo University hospital, kindly supported by the International Federation of Clinical Chemistry and Laboratory Medicine, Professional Scientific Exchange Program. The purpose of this educational visit was to improve my capacity of applying the advanced technology, particularly Liquid Chromatography Mass Spectrophotometry (LC-MS), in diagnosis and monitoring of congenital adrenal hyperplasia.

The routine analysis of steroid hormones is critical in understanding the function of metabolic pathways that impact sexual characteristic particularly in patients with congenital adrenal hyperplasia and disorder of sex development. LC-MS/MS is a robust emerging technique in steroid analysis due to the advantages it provides over immunoassay. These benefits include improvements in analytical sensitivity and selectivity, and the capability of multi-analyte quantitative detection in a single run.

Dr. Vivek Pant and Prof. Per Medbøe Thorsby

I spent most of my time at the LC-MS lab learning the analysis of steroids in blood samples. I observed and I was explained in detail about the whole process of sample preparation to interpretation of mass spectra. Sample preparation is the most important part to learn during LC-MS analysis of steroids. It is essential to remove proteins and other constituents that may precipitate when injected into the liquid chromatography (LC) mobile phase, to avoid clogging the chromatography column and improve chromatographic performance. The volume, pH, organic solvent, buffer and aqueous composition of the liquid injected into the LC have a profound effect on chromatography, modifying LC peak shapes, peak separation and retention times. This ultimately affects the quantitation limits, selectivity and robustness of the assay.

I had one to one sessions with Prof. Per Medbøe Thorsby, the quality manager

Article continued on next page

Stine Rødmyr, research scientist Alexander Bauer Westbye and Sandra Rinne Dahl, Dr. Finn Erik Aas and Dr. Oskar Kelp. The hormone laboratory at Oslo university hospital has validated the use of serum samples for multi-steroid profiling by LC-MS/MS technology. This laboratory uses an in house LC-MS/MS method developed for determination of serum concentrations of testosterone, androstendione, 17-hydroxyprogesterone, 21-deoxycortisol, 11-deoxycortisol, deoxycortisosterone, corticosterone, cortisone and cortisol. The optimized use of these analytes in research will allow us to gain further insight into the steroid metabolism in patients with congenital adrenal hyperplasia.

While rotating in the laboratory I was provided with the opportunity to present about my workplace and my scientific publications. Also, I had the opportunity to visit the newborn screening laboratory where LC-MS technique was in use for analysis of various compounds other than steroid. Dr. Ingjerd Saeves explained about the analysis of different analytes by LC-MS in first and second tier methods that were either developed in-house or adopted from the literature. In newborn dried blood spot samples, the amino acids, acylcarnitines and succinylacetone were quantified by flow injection analysis with ultra-performance LC-MS. The in-house developed LC-MS/MS method was also used to measure homocysteine, methylmalonic acid and methylcitric acid and to differentiate pivaloylcarnitine from isovalerylcarnitine.

The faculties and staff at the hormone laboratory made me feel as a part of the team and everyone was very kind and always willing to answer all my queries. I also got to know the new things about the techniques and quality control management I was already familiar with, which I can introduce in my laboratory to improve and make it more efficient. Moreover, I have seen best possible ways of working, organizing, and managing a LC-MS laboratory which has broaden my views.

I am very impressed by the collegial environment, state-of-the-art research facilities and the egalitarian structure in the Oslo university hospital.

I must extend my heartfelt gratitude to Prof. Per Medbøe Thorsby, who believed in me and provided his facilities at the hormone laboratory for my learning process.

I am grateful and indebted to prof. Bharat Jha and assistant prof. Ram Vinod Mahato representing the Nepalese Association for Clinical Chemistry (NACC). Finally, I would like to thank the IFCC that offers this wonderful opportunity to the young researchers and brings together the researchers and laboratory personnel around the globe.

Oslo University Hospital - the Hormone Laboratory is in building no. 23

On-demand content available for the IFCC Live Webinars on "Challenges in laboratory diagnosis of endocrine diseases" that was held on 21 September 2022



To access the recording, click here.

On-demand content available for the IFCC Live Webinars on "Aspects of Newborn Screening" that was held on 5 October 2022



To access the recording, click here.

IFCC Webinars

Sponsored by
Siemens Healthineers
Boston Children's Hospital

Live Series

2022

www.ifcc.org

IFCC International Federation of Clinical Chemistry and Laboratory Medicine

IFCC complimentary Webinar

19th October, 2022

"From Data to Decisions: Data and Analytics Leadership in Clinical Laboratory Management"

Register here

Certificate of Participation available for all registrants!

IFCC Live Webinar on

From Data to Decisions: Data and Analytics Leadership in Clinical Laboratory Management

Moderator

Prof. Sedef Yenice [Turkey]
Prof. Sedef Yenice
Professor of Biochemistry and Clinical Laboratory Medicine
Demiroglu Bilim University and G Florence Nightingale Hospital, Turkey

Data & Analytics leadership: Challenges and opportunities

Dr. Praveen Sharma [India]
Professor of Biochemistry
All India Institute of Medical Sciences, Jodhpur, India

Laboratory Data Analytics to improve patient experience and deliver more value

Dr. Merve Sibel Güngören [Turkey]
MD-PhD, EMBA; Specialist in Medical Biochemistry
Düzen Laboratories Group, Turkey

Continuous improvement strategies in clinical laboratory services with Data Analytics

Dr. Raja Elina Raja Aziddin [Malaysia]
Senior Technical Assessor
Malaysian Association of Clinical Biochemists

Date: Oct 19, 2022
Time: 8 AM (Eastern Standard), 2 PM (Central European), 8 PM (Beijing)

IFCC 70th ANNIVERSARY 1952 2022 International Federation of Clinical Chemistry and Laboratory Medicine

Article continued on next page

Dear colleagues,

The next IFCC webinar: “From Data to Decisions: Data and Analytics Leadership in Clinical Laboratory Management” will be held on October 19, 2022.

Clinical laboratories are major data sources of healthcare. The changing landscape of healthcare industry forces clinical laboratory leaders to meet the needs of their stakeholders, maximize operational efficiency and improve overall quality of patient care at the same time. The increasing number of data produced daily drives the clinical laboratory leaders to navigate their strategies. Not only the patient results, but also data produced during total testing process are very beneficial to give insight for managerial decision-making. However, there are still some challenges like accessing, processing, sharing, real-time analysis and visualization of data in clinical laboratories.

This webinar will focus on how to adopt Data and Analytics Leadership approach in clinical laboratories to gain competitive advantage in the new era.

Prof. Dr. Praveen Sharma will give a presentation on “Data & Analytics leadership: Challenges and opportunities” This will be followed by Dr. Merve Sibel Gungoren’s talk on “Laboratory Data Analytics to improve patient experience and deliver more value” The last lecture will be given by Dr. Raja Elina Raja Aziddin and will cover the topic of “Continuous improvement strategies in clinical laboratory services with Data Analytics”.

This webinar comprises of three following presentations of 20 min each followed by 20 min of panel discussion at the end.

Chair/Moderator: Prof. Sedef Yenice

Talk 1: “Data & Analytics leadership: Challenges and opportunities” - Dr. Praveen Sharma

Talk 2: “Laboratory Data Analytics to improve patient experience and deliver more value” - Dr. Merve Sibel Güngören

Talk 3: “Continuous improvement strategies in clinical laboratory services with Data Analytics” - Dr. Raja Elina Raja Aziddin

- **Schedule:** 20 min per speaker plus 20 min panel discussion
- **Time Zones:**
  Live presentations starting at: 8:00AM EDT-New York; 2:00PM CET-Rome; 8:00PM CST-Beijing;
  Important: Please ensure that you carefully determine the time that the presentation will start in your global time zone. Click here *to convert to your time-zone.*
- **Recorded webinar***: available on demand*
- **Certificate of participation***: available for all registrants*

CONTRIBUTE TO IFCC eNews

Left to right: Peter Baxter, Neil Mahon, Shaun Francis, Yogini Walli, Peter Nord

Article continued on next page

Ever wondered what it would be like to have a glimpse into your cardiovascular health? Tens of thousands of people in Canada not only wonder but proactively seek annual cardiovascular health assessments. In a world where cardiovascular diseases continue to be the leading killer globally, early and accurate health information could be game changers.

As a Canadian leader in annual cardiovascular health assessments, Medcan Health Management Inc. in Ontario, Canada just received prestigious recognition of Distinction for global healthcare excellence with the UNIVANTS of Healthcare Excellence program.

Medcan has been providing comprehensive annual health assessments (AHA) for the past 25 years, with an increase in clients annually. The cardiovascular portion of the health assessments had long included a stress test among many other factors. The stress test, however, was replaced during the COVID-19 pandemic with an objective blood biomarker. Ironically, the additive blood biomarker not only met the real-time requirements of assessing cardiovascular health but gave a glimpse into the future with respect to individual cardiovascular risk.

More specifically, an integrated clinical care team at Medcan replaced stress testing through implementation of high-sensitivity cardiac troponin testing (hs-cTnI) in order to enhance and improve identification of future risk of cardiovascular disease. Successful implementation has had significant impact across stakeholders, including their clients, clinicians, administration, and entire health system Within the first 6 months over 8,000 clients were screened as part of an annual CV health assessment, enabling identification of 204 clients as high risk for future cardiovascular events. Of those, 451 clients at moderate risk and 7,392 at low risk of future cardiovascular events. Detection enabled the commencement of appropriate preventative care and education across each level of risk. Additional benefits included a mitigated annualized savings of $284,400 CND for Medcan and $357,500 CND for the Canadian Healthcare System based on improved overall specificity. Finally, substantial time savings were realized for both clients and physicians, with average time saved of 38 minutes per client AHA and 45 minutes per day for each attending physician included in AHAs.

For their efforts in preventative medicine and innovative use of high-sensitivity cardiac troponin, this integrated clinical care team from Medcan was awarded the prestigious honor of distinction in association with the 2021 UNIVANTS of Healthcare Excellence Awards. Congratulations to Peter Nord, MD, Chief Medical officer at Medcan, Peter Baxter, BA, Director, Clinic and Corporate Application Services, Technology Services at Medcan, Shaun Francis, MBA, Chair and CEO of Medcan, Neil Mahon, MSc, PMP Chief Information Officer at Medcan, Yogini Walli, MSN Director, Clinic Services at Medcan.

To learn more and apply for the 2022 awards, please visit www.UNIVANTShce.com.

The deadline for 2022 applications is November 15, 2022.

UNIVANTS™
OF HEALTHCARE EXCELLENCE

DON'T MISS OUT...

ACT NOW!

UNIVANTS™
OF HEALTHCARE EXCELLENCE

The **UNIVANTS** of Healthcare Excellence Award recognizes teams who collaborate across disciplines and transform healthcare delivery, and ultimately patient lives.

Submit your team application to the **UNIVANTS** of Healthcare Excellence Award program on or before November 15th **at UnivantsHCE.com.**

The time is now to highlight your healthcare excellence!

Abbott

IN PARTNERSHIP WITH

ifcc International Federation of Clinical Chemistry and Laboratory Medicine
AACC
EHMA European Health Management Association
Modern Healthcare
HIMSS
NAHQ National Association for Healthcare Quality
IHE INSTITUTE OF HEALTH ECONOMICS

Article submission process streamlined for Clinica Chimica Acta and related journals

by Laura Guilherme Luzia
Scientific Managing Editor, Author Heroes Elsevier

Submitting an article for publication is an essential step in the research process, but finding the right journal can be challenging. Often authors' first choice of journal turns out to be incorrect, requiring them to resubmit their article elsewhere, which can be a complex and time-consuming process.

Now, an initiative by Elsevier LV (Amsterdam, Netherlands), one of the world's largest scientific publishers with around 300 journals including Clinica Chimica Acta, recognizes this process isn't always smooth, and aims to help authors find the best journal match for their article, quickly and easily.

To achieve this, a dedicated team of scientific editors use their subject-matter knowledge to analyze manuscripts, provide guidance and tailored recommendations for transfers to another Elsevier journal, working closely with editors from both originating and destination journals.

Authors who have received rejections, either before or after peer review, will be able to accept a transfer offer to a more suitable journal.



The program is designed to make the editorial process smoother and more efficient, so that transferred articles will flow through the Elsevier editorial submission system. This comes with the advantage that in many instances, authors won't need to reformat the article but still have the option to make revisions if they want. Additionally, previous comments from editors and referees can be transmitted with the manuscript, ensuring all parties benefit from previous insights.

The most common types of transmissions are pre-review and post-review, where editors of the destination journal will make their own assessment based on the materials they receive. When the editor of the originating journal considers that an article is acceptable for publication in another journal, Elsevier's scientific managing editor can offer an enhanced offer to authors such as Recommended Acceptance, Guaranteed Peer-Review or Fast-Track Processing by the suggested journal.

For Recommended Acceptance, provided that authors address comments from the original editors/referees, and follow the instructions given in the transfer offer, publication in the alternative journal is expected without further peer review. Laura Guilherme Luzia, a scientific managing editor at Clinica Chimica Acta, added, "Elsevier's Article Transfer Service team understands that authors are unique, and that each article deserves to find its most suitable journal."

Related links: Elsevier BV, Clinica Chimica Acta, Elsevier Article Transfer Service.

The First IFCC-Mindray International Case Contest in Laboratory Medicine: congratulations to the winners!

by Khosrow Adeli
IFCC President

The 1st International Laboratory Medicine Case Contest organized by IFCC in collaboration with the Mindray was successfully held from May to August. This event was themed “Laboratory: Vital to clinical diagnostic support and patient care” and was divided into Online one for International applicates (out of China) and offline one for Chinese applicates.

Co-organizers for Online Contest:
IACPaLM (Indonesian Association of Clinical Pathology and Laboratory Medicine)
TBD (Turkish Biochemical Society)
CAHO (Consortium of Accreditation Healthcare Organizations)



Co-organizers for Offline Contest:
Guangdong Provincial People’s Hospital
Laboratory Medicine New Media
International Journal of Laboratory Medicine

260 entries (180 from China and 80 from other countries) were received from more than 240 laboratory peers representing 21 countries which are China, Indonesia, Argentina, India, Turkey, Bangal, Burundi, Canada, Chile, Colombia, Ecuador, France, Malaysia, Oman, Pakistan, Poland, Russia, Spain, Sri Lanka and Panama. Around 80 cases made it to the second round, which are all very typical, rare or special cases, providing valuable experience for clinical doctors,spanning subject areas such as Immunology, Hematology, Chemistry, Microbiology, Urine, and Molecular.

Article continued on next page

Here is a list of the top winning cases. Congratulations to all the winners!

Format	Award	Country	Institution	Topic	Author
Online	First Prize	France	1 Univ. Lille, CNRS, UMR 8576 – UGSF - Structural and Functional Glycobiology Unit, F-59000 Lille, France 2 Univ. Lille, CHU Lille, Genetic Pathology Biology Pole, Institute of Biochemistry and Molecular Biology, UAM of Glycopathologies, F-59000 Lille, France	A novel transferrin variant impairs the diagnosis of alcohol abuse and congenital disorders of glycosylation	Elodie Lebredonchel
		Indonesia	Clinical Pathology Department, Medical Faculty of Universitas Brawijaya, dr. Saiful Anwar General Hospital, Malang, Indonesia	Transient Abnormal Myelopoiesis-Down Syndrome with Thrombocytosis in 24-days-old Infant	Achmad Arrizal
	Second Prize	Poland	Central Laboratory, University Clinical Centre of Medical University of Warsaw	Psychiatric symptoms with autoimmune background.	Pawel Kozlowski
		Malaysia	Universiti Tunku Abdul Rahman (UTAR), Malaysia	The Unexpected Relapse of Diffuse Large B-cell Lymphoma (DLBCL)	Dr. Lee Bee Sun
		Indonesia	Clinical Pathology Department, Medical Faculty of Universitas Brawijaya, Malang Indonesia	Secondary Hemophagocytic Lymphohistiocytosis in a 55-year-old Female	Khoirunisah Dwi Hartanti
		Argentina	Hospital de Niños R. Gutiérrez. Gallo 1330. Ciudad autónoma de Buenos Aires, Argentina	Immune-mediated thrombotic thrombocytopenic purpura (TTP) in pediatrics	María Inés Marcone Laura Colitto Macarena Ottobre, Agustina Nosetti
		Argentina	Hospital de Infecciosas Francisco Javier Muñíz	Relevance of serum cortisol dosage in patients with disseminated histoplasmosis	Gauder, Catalina Zambrano, María Pirén Labarta, Natalia Bocassi, Andrea Astudillo, Germán
	Third Prize	Indonesia	Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia	Hepatitis C Infection and Autoimmune Hemolytic Anemia in a Patient with Colon B-Cell Non-Hodgkin Lymphoma	Dearikha Karina Mayashinta
		Argentina	Hospital General de Agudos “Juan A. Fernández”	The role of the Laboratory in the diagnosis of Monoclonal Gammopathy	del Bustio, María Florencia Labarta, Natalia Palma, María Belén
		India	Rainbow children’s hospital and Mithra multispecialty hospital	Variance of Blood and CSF glucose levels as a clue to rare GLUT -1 deficiency type 1 syndrome	Dr. Karuna Rameshkumar Dr. Ann Agnes Mathew
		Turkey	Antalya Research And Education Hospital	Atypical Cells in Urinalysis Urge the Surgeon for Further Investigation for Urothelial Carcinoma	Feyza Yağmur Tekeli Özgür Aydın Deniz Bayar Armagan Gunal
		India	Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute	Acute Kidney Injury and developing the electronic patient record in India-Is it possible?	Dr. Barnali Das, Ms. Urja Parekh, Ms. Poonam Mandavkar Pal, Dr. Sharad Sheth, Dr. Niranjan Kulkarni, Dr. Santosh S Shetty

Article continued on next page

Offline	**First Prize**	China	The First Affiliated Hospital of Guangzhou Medical University	The ultimate confession after 20 years-Write a “poem” for you	Chen Wanjun
			The Affiliated Hospital of Southwest Medical University	Karyotype analysis, unraveling the mystery of gonadal tumour hidden etiology	Zhou Jiahong
	Second Prize		Maternal and Child Health Hospital of Hubei Province	Application of metagenomics next-generation sequencing in a febrile 5-year-old patient with neutropenia	Zhu Yaqi
			The First Hospital of China Medical University	Hypoglycemic Mystery	Zhou Bo
			Peking University Shenzhen Hospital	A Novel Nonsense Mutation in the Androgen Receptor Gene Causes the Complete Androgen Insensitivity Syndrome	Wang Qiu
			Guangdong Women and Children Hospital	A case of “pulmonary isolated infection” by Tropheryma whipplei in a six-year-old child	Bai Ru
			The First Affiliated Hospital of Sun Yat-Sen University	A detective tour on mixed infection pneumonia	Chen Yili
			Jiangxi Maternal and Child Health Hospital	A case of asparagine synthetase deficiency	Lu Wan
	Third Prize		The First Affiliated Hospital of Guangxi Medical University	Diagnostic value of metagenomic next-generation sequencing for Ureaplasma urealyticum infection in a patient with β thalassemia	Ruan Xuelian
			Zhejiang Provincial People’s Hospital	Atypical presentation of thiamine-responsive megaloblastic anemia in a Chinese baby boy	Liu Jinlin
			Shenzhen Luohu Hospital Group	A case of prenatal diagnosis of complex chromosomal rearrangement in a fetus associated with a paternal pericentric inversion	Ji Xiang
			Nanfang Hospital Southern Medical University	Fever with hemophagocytic syndrome secondary to Hantavirus infection : a case report	Zhang Ruyi
			Guangdong Provincial People’s Hospital	A mistery of a decade: Who is the real culprit?	Tian Benshun
			The First Affiliated Hospital of Guangxi University of Chinese Medicine	Three blood glucose results in one sample, which is right and which is wrong?	Tang Yinghua
			Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University	Dysentery caused by a protozoon in North China	Yu Peixia
			Chongqing Traditional Chinese Medicine Hospital	A case of type 2 diabetic ketoacidosis was found by discovering an abnormal elevation of HGB	Zhou Fangzhu, Wang Zimeng
			The First Affiliated Hospital of Xiamen University	Pretender-ETP-ALL	Zhou Yiyan, Liu Shuojie
			Central People’s Hospital of Yichang	Tinea capitis caused by Microsporum canis in a 3-year-old boy	Min Doudou
			The Second People’s Hospital of Shenzhen	Thrombosis or Hematoma	Huang Chunxiu
			Guangdong Provincial People’s Hospital	Peritonitis caused by Neosartorya hiratsukae in a dialysis patient, China	Wang Xiaoxiao

Article continued on next page

Please click on the video link below to look at the informative, clinically valuable case studies covering all disciplines from laboratory peers.

Topic	Youtube link
A novel transferrin variant impairs the diagnosis of alcohol abuse and congenital disorders of glycosylation — France	https://youtu.be/0NVc-KgeXKw
The Unexpected Relapse of Diffuse Large B-cell Lymphoma (DLBCL) — Malaysia	https://youtu.be/b_HP3SZ8mK4
Immune-mediated thrombotic thrombocytopenic purpura (TTP) in pediatrics — Argentina	https://youtu.be/0edNnl0r8V0
Transient Abnormal Myelopoiesis-Down Syndrome with Thrombocytosis in 24-days-old Infant — Indonesia	https://youtu.be/ZxZNCjGRu7M
Psychiatric symptoms with autoimmune background. — Poland	https://youtu.be/5p_dAfokETE
Acute Kidney Injury and developing the electronic patient record in India-Is it possible? — India	https://youtu.be/qqq_m_XLm4Q
Secondary Hemophagocytic Lymphohistiocytosis in a 55-year-old Female — Indonesia	https://youtu.be/3EwcY0cJbgw
Atypical Cells in Urinalysis Urge the Surgeon for Further Investigation for Urothelial Carcinoma — Turkey	https://youtu.be/IpGJbSv8t3w
Variance of Blood and CSF glucose levels as a clue to rare GLUT -1 deficiency type 1 syndrome — India	https://youtu.be/qetUrlfRmPM
Hepatitis C Infection and Autoimmune Hemolytic Anemia in a Patient with Colon B-Cell Non-Hodgkin Lymphoma — Indonesia	https://youtu.be/LRmaVEi67yc
Relevance of serum cortisol dosage in patients with disseminated histoplasmosis — Argentina	https://youtu.be/1vExHoTsA9o
The role of the Laboratory in the diagnosis of Monoclonal Gammopathy — Argentina	https://youtu.be/vCbH-6Ypo14
The ultimate confession after 20 years-Write a “poem” for you	https://youtu.be/7DxIfamUtyk
Karyotype analysis, unraveling the mystery of gonadal tumour hidden etiology	https://youtu.be/hJQhBBXh6Oo
Application of metagenomics next-generation sequencing in a febrile 5-year-old patient with neutropenia	https://youtu.be/D2NF4lEFs5Q
Hypoglycemic Mystery	https://youtu.be/N1PI3A5HcFw
A Novel Nonsense Mutation in the Androgen Receptor Gene Causes the Complete Androgen Insensitivity Syndrome	https://youtu.be/C-7GTlsELZQ
A case of “pulmonary isolated infection” by Tropheryma whipplei in a six-year-old child	https://youtu.be/vS7Wu8BGUys

Article continued on next page

A detective tour on mixed infection pneumonia	https://youtu.be/C-7GTlsELZQ
A case of asparagine synthetase deficiency	https://youtu.be/TuRkAz0VIxg
Diagnostic value of metagenomic next-generation sequencing for Ureaplasma urealyticum infection in a patient with β thalassemia	https://youtu.be/ISs-rpBgD1Y
Atypical presentation of thiamine-responsive megaloblastic anemia in a Chinese baby boy	https://youtu.be/GNDNRpK-JRY
A case of prenatal diagnosis of complex chromosomal rearrangement in a fetus associated with a paternal pericentric inversion	https://youtu.be/uL7C1lPqyo8
Fever with hemophagocytic syndrome secondary to Hantavirus infection: a case report	https://youtu.be/xLt7VSFQlUg
A mistery of a decade: Who is the real culprit?	https://youtu.be/2rfDxmeTKh0
Three blood glucose results in one sample, which is right and which is wrong?	https://youtu.be/Tsxx3dtoqH0
Dysentery caused by a protozoon in North China	https://youtu.be/A4SAJeS9APk
A case of type 2 diabetic ketoacidosis was found by discovering an abnormal elevation of HGB	https://youtu.be/TXAXU0C18o4
Pretender-ETP-ALL	https://youtu.be/REijkfzETPM
Tinea capitis caused by Microsporum canis in a 3-year-old boy	https://youtu.be/p6M6zKicyek
Thrombosis or Hematoma	https://youtu.be/dqMdVGfmcXs
Peritonitis caused by Neosartorya hiratsukae in a dialysis patient, China	https://youtu.be/F1Syu2e-WMg

Spanish Society of Laboratory Medicine (SEQC^{ML}) unveils new Strategic Plan for improving patient health

Sociedad Española de Medicina de Laboratorio

by Mercè Ibarz Escuer, PhD
SEQC^{ML} - IFCC National Representative
Laboratori Clínic ICS Lleida
Hospital Universitari Arnau de Vilanova
Lleida, Spain

The SEQC^{ML} is committed to the humanization of clinical laboratories in its new Strategic Plan (2022-2024):

- **The Society's 2022-2024 Strategic Plan seeks to promote Laboratory Medicine specialties through the implementation of research projects using multi-centre registration and the creation of an SEQC^{ML} Observatory.**
- **The Society will create a working group to assess the impact of the 2030 agenda on Laboratory Medicine and identify the measures that will need to be adopted to move towards a green laboratory.**
- **It will promote among scientific societies patient-oriented care and the incorporation into their strategic plans of 5P medicine: personalized, predictive, preventive, participative, and population-based.**

Madrid, September 5, 2022 – The humanization of clinical laboratories and the creation of an Observatory for the dissemination of current issues in Laboratory Medicine are some of the strategic objectives of the new 2022-2024 Strategic Plan of the Spanish Society of Medicine Laboratory (SEQC^{ML}), the goal of which is to improve patient health. The new project, developed over a period of eight months, is aimed at guiding the actions of the Board of Directors and the SEQC^{ML} during this three-year period. The Strategic Plan has been developed in several phases, including a massive survey of members, and has been put together thanks to the work of a committee of experts made up of members independent of the Board of Directors.

The new Strategic Plan consists of a total of 50 actions and nine strategic lines to be implemented. Among them, the president of the SEQC^{ML}, Dr. Antonio Buño, highlights the *Humaniza Program*. "We are seeking to develop a humanization policy aimed at clinical laboratories in the pre-analytical phase and at the time of sample collection, to ensure humanized care for patients, family members, and companions," he explains.

The commitment to 5P medicine (personalized, predictive, preventive, participative, and population-based) and the promotion of patient-oriented care among scientific societies are also key elements of the project. In addition, the new Strategic Plan is committed to the development of formulas for collaboration between laboratory specialists and professionals from other specialties and the promotion of personalized medicine linked to molecular biology.

Likewise, it seeks to promote Laboratory Medicine specialties through various actions. In particular, the aim is to carry out research projects using a multi-centre registry where a large number of laboratories can participate, the development of a channel of good practices, and the launch of a SEQC^{ML} Observatory "for the monitoring and dissemination of current issues, successful experiences, and trends in Laboratory Medicine", explains Dr. Antonio Buño.

Article continued on next page

The Society is also proposing the creation of a working group to assess the impact of the 2030 agenda on Laboratory Medicine and identify the measures that will have to be adopted to move towards a green laboratory.

LESSONS LEARNED

The new Strategic Plan has detected a series of areas for improvement and a number of barriers to overcome. One of them is the lack of recognition of the contribution of Laboratory Medicine and the clinical laboratory in diagnostic and research work. In addition, there is an excessive demand for laboratory tests and an increase in costs, which can generate, according to the president of the SEQC^{ML}, "a biased image of the clinical laboratory and Laboratory Medicine among hospital management or regional health services".

@SEQC_ML
Residentes del Laboratorio Clínico - SEQC
SEQC-ML
seqresidentes

Smart interconnected minds at the 16th BCLM2022 – Tallinn, Estonia

by Bernard Gouget
Chair, IFCC-C-MHBLM

Summer has come to an end. The 16th Baltic congress in Lab Medicine, true translational hub of innovation in lab medicine practice, took place on September 22-24th in Tallinn (EE), bringing together specialists in lab medicine, students and health care professionals from the three Baltic States: Estonia, Latvia, Lithuania as well as other countries.These three Baltic countries have common health issues. During this meeting, they were able to pool their knowledge, experience and resources.

Estonia is the smallest of the Baltic countries both in land area and population (1,328 000), with a high-income advanced economy, ranking very high in the Human Development Index. Tallinn, the capital city of Estonia is a little gem in the Baltic states, rich in culture and natural wonders. This year, the weather at the beginning of autumn was still warm and the nature was bursting with crimson, gold, brown and orange. The invitation by Professor Anu Tamm, President of the congress, allowed me to come and meet our Baltic colleagues.

The hotel was a few meters from the old town of Tallinn surrounded by medieval fortifications from the end of the 13th century. The view from the top floors was fantastic: the church of St Olav, the spire of the town hall tower and the spectacular Alexander Nevsky Cathedral built in 1900, an onion-domed structure perched at the top of the Toompea Hill. It is by far the grandest, most opulent Orthodox church in Tallinn.

The congress, held only once every two years, is the unique opportunity to consider and discuss opportunities and challenges regarding the evolution of laboratory medicine. In the current post-pandemic situation, it was important to meet the IVD industry representatives at the exhibition and to discover new technologies and latest innovations. The congress was located at the Tallinn Song Festival grounds. This sprawling event venue

in Kadriorg holds a special place in Estonians' hearts as the birthplace of the Singing Revolution. It was here in 1988 that Estonia's massive, musical demonstration against Soviet rule set the nation on its road towards re-independence.

The opening ceremony started on Thursday at 6pm with the welcome address by Professor Dalius Vitkus, Lithuania, who presented, in a dynamic way the history of the BCLM congress that started in 1992 in Tartu, Estonia. As EFLM EB member, he recalled that EFLM is the largest region within IFCC and described the EFLM structure and its mission to enhance patient care and improve outcomes by promoting and improving the scientific, professional and clinical aspects of clinical chemistry and laboratory medicine ensuring effective representation of laboratory medicine both at European Union level and to other pan-European and sub-regional bodies. A special attention was given to the EFLM academy as well as to the Syllabus course.

Professor Anu Tamm (EE), President of the congress, delivered the opening lecture on DigiLab and Harmonization in Estonia. In Estonia, there are 26 clinical labs (1 private, 3 regional hospitals, 4 central hospitals, 13 county or specialized hospitals, 1 lab of Health board, 4 specialized genetic labs). The process of laboratory data harmonization in Estonia started with the unification of the terminology and units. The state institution, Health and Welfare Information System Centre (TEHIK) generated aHL7 based standard for lab data flow with the aim to collect data centrally. A local public data base of lab tests was created. The Estonian Society of Lab Medicine is responsible for the validity of data in the database. Laboratories should register all the tests they run in

L-R: Anu Tamm (EE), Agnes Ivanov (EE), Sverre Sandberg (NO), Anders Karllner (SW), Bernard Gouget (FR)

Article continued on next page

ELHR, and thus, information about their test menus is available. By now, the majority of clinical labs report their data to the HER which is accessible by all relevant medical personnel and each person individually. In order to optimize the use of medical data, TEHIK is developing a platform named Data Viewer, providing a condensed overview of all health information delivered by different health institutions. Estonia has one of the leading eHealth systems in Europe.

Professor Sverre Sandberg (NO) opened the first day of the congress speaking on biological and analytical variation of biomarkers. Data biological variation are used for many purposes, the most common is to set performance specifications, to generate personal reference intervals and, calculate reference range values and index individualities. An EFLM Task Group cooperates with the analytical quality commission of the Spanish society (SEQC) and the WG on Biological variation (WG-BV). They developed a critical appraisal check list to evaluate the literature on biological variation and extract essential information. The WG-BV has collected data from about 100 healthy individuals in six EU countries and is now generating new data for many measurands.

Professor Kalle Kisand, Chair BCLM SC-Committee

The program featured case presentations, round tables, interactive debates in plenary and group sessions and IVD commercial presentations. Highlights included sessions on the different disciplines of lab medicine.

A morning session was dedicated to hematology and coagulation. The hemogram reference values in Estonia were discussed by K. Tomberg (EE). Diagnosis of multiple myeloma risk estimation includes disease burden, end-organ damage, and biomarkers, with increasing emphasis on genetic abnormalities. Multicolor flow cytometry (MFC) is not always considered in risk estimation. M. Radzevicius et al. (LT) demonstrated associations found between genetic abnormalities and antigen expression of plasma cells measured by MFC. They uncovered specific immune-phenotype features related to different genetic risk factors. Specifically, they found higher malignant/normal plasma cell ratio and lower expression of CD27, CD38, CD45, CD56, CD117 and CD138 in higher-risk genetic groups or risk categories. L. Volozonoka (LV) spoke on myths and truth on changes in genes involved in coagulation.

Clinical genetics and rare diseases dominated the end of the morning. Next generation sequencing (NGS) has transformed the diagnostic of rare diseases by significantly accelerating the identification process of the hereditary diseases said G.Petraityte (LT). K Grigalioniene (LT) insisted on the significant improvements in the diagnosis of the mitochondrial diseases (MDs) with the use of NGS. However, a substantial fraction of patients remains undiagnosed.

Afternoon sessions were organized in parallel. We learned a lot on the latest updates of the new In Vitro Diagnostic Regulation (IVDR) for Clinical laboratories and the implications of the in house IVD'S. Anders Kallner (SW) discussed the importance of comparability,

Article continued on next page

compatibility and transferability of results. I. Lutsar (EE) spoke on emerging and reemerging infection diseases in 2022. The Covid-19 pandemic painfully showed the reasons why nations are better off when they cooperate and collaborate in health issues, and also revealed the hazards of their incomplete commitment in doing so. J. Geller (EE) drew our attention to the fact that Estonia belongs to an endemic region with a high incidence of tick-borne encephalitis and Lyme borreliosis.

In the past two years, Covid-19 has taken a toll on cancer prevention, detection, and diagnosis. The sooner cancer is detected, it can make a real difference by increasing treatment options and saving lives. For this, we need to boost cancer screening across the EU. As part of the EU Cancer Screening Scheme to be put forward under Europe's Beating Cancer Plan, the Commission has a new approach to support Member States increasing the uptake of cancer screening and focusing on detection of cancers at an early stage. The objective of the proposed recommendation is to increase the number of screenings, covering more target groups and more cancer cases. This new EU approach, based on the latest available scientific developments and evidence, will support Member States ensuring that 90% of the EU population who qualify for breast, cervical and colorectal cancer screenings are offered such screening by 2025. The new recommendation expands population-based organized cancer screening to include lung, prostate and, under certain circumstances, gastric cancers. K. Reimand (EE), V. Petekevicious (LT), T. Zabocka (LV) presented a comparative approach to the deployment of these programs today in the three Baltic countries.

The second day started with my lecture on smart lab medicine in the digital era. The future of the medical laboratory is the stuff of science fiction. The world of biomedical innovation is complex and diverse, full of promising technologies that will improve care. Smart medical devices market is driven by the increase in demand for smartphone compatible devices. An ever-expanding array of technologies is being used for m-Health from the basic to the complex (mobile apps and wearable devices) to the futuristic (tattoo, implantable and ingestible devices). E-Health is becoming engrained in the world of health. With the development of information technology, the concept of smart healthcare is gradually coming to the fore. Smart healthcare uses a new generation of information technologies, such as the internet of things (IoT), big data, cloud computing, and artificial intelligence, to transform the traditional medical system in an all-round way, making healthcare more efficient, more convenient and more personalized. Due to the Covid-19 pandemic, smart technologies have been rapidly and widely implemented as the 'new healthcare standard' allowing for the provision of the right care for the right patient at the right place.

Point of care testing (POCT) devices have the potential to enhance clinical decision-making, accelerate time to treatment, reduce inappropriate conveyance and reassure patients. They may, therefore, have an enabling role to play in the urgent care delivery by out-of-hospital care services. Sverre Sandberg, who

Professor Anu Tamm, President BCLM 2022 and Professor Dalius Vitkus, EFLM EB Member; BCLM 2024 will be held in Lithuania

Article continued on next page

is very well-known expert on quality and POCT, explained that since POCT is carried out different environment with different users and often with different performance specifications and different types of in-built controls, we have to reevaluate how and which types of quality control should be used. Agnes Ivanov (EE) reported a clinical study for future use of POCT in the Tartu ambulance service. She summarized all the available evidence on the impact of introducing blood-based point-of-care panel testing (POCT) in the ambulance on patient outcomes and hospital processes. Marge Kütt (EE) underlined the increasing interest of the patient or consumer to understand why a test was done and comprehend the meaning of the result. Patients' direct access to test results through online portals is increasing. They may discuss test results with family and friends or seek information on the internet. The responsibility for explaining test results lies between medical biologists and clinicians considering the patient's literacy and skill level; clinicians should explain clearly what the results mean and treatment choices. The sessions on harmonization, on STI, HPV, HIV as those on Covid 19, in general were glowing.

Prof. KalleKisand, Chair of the Scientific Committee, coordinated the presentation of selected abstracts. Three young scientists: O. Savicka (LV), B. Niedre-Otome (LV) and M. Keernik (EE) were awarded. The next scientific BCLM congress will be held in Lithuania in 2024.

After so much science, we were able to relax and dive into an underwater atmosphere in the unforgettable Sea-plane harbor, home to a super-modern maritime and military museum. Its architecturally unique hangars, built a century ago, are the world's first reinforced concrete shell structures of such of great size.

Congratulations to BCLM, it was an energizing and uplifting experience, a very inspiring congress to envisage our future together!

Dr. Jean-Baptiste Woillard (FR) winner of the «1st IFCC-Gérard Siest Young Scientist Award for Distinguished Contributions in Pharmacogenetics»

by Dr. Jean-Pascal Siest
Président Biologie Prospective

Professor Gérard Siest

With the presentation of the first «IFCC - Gérard Siest Young Scientist Award for Distinguished Contributions in Pharmacogenetics» in Seoul 2022, it is a great honor to do this in memory of my father, known as the smiling IFCC President. Prof. Gérard SIEST was IFCC President from 1991 to 1996. He introduced the concept of laboratory medicine and succeeded in ensuring that many countries worldwide joined IFCC. Until his sudden death on April 9, 2016 just after the General Conference in Madrid 2016, he was a non-stop creative scientist. Always looking to the future, Prof. Gérard SIEST created and chaired the European Society of Pharmacogenomics and Personalized Therapy (ESPT). Therefore, it is natural that the "Gérard SIEST- biology prospective Award" prizes a young leader in the field for his/her contribution to progress in pharmacogenomics and personalized medicine.

As he would have loved, It was quite normal that the "Gerard Siest award" celebrates medical science, youth and innovation. On behalf of Biologie Prospective, we would like to personally thank Dr. Bernard Gouget, who was President-IFCC General Conference Madrid 2016

Article continued on next page

Plaque honouring Dr. Jean-Baptiste Woillard

and Chair IFCC nominations committee in 2017, and much-lamented Prof. Howard Morris, brilliant IFCC President, to convince me during the WorldLab Durban to create a new IFCC award dedicated to my father. We thank them from the bottom of our hearts as well as the entire IFCC office for their technical assistance.

Because of the sanitary restrictions, it was not possible for me to be present in Seoul. Thank you to our colleague Prof. Tomas Zima, member of the IFCC Awards committee for representing me and for giving this award. He was a close friend of my father and, as Rector of Charles University in Prague, he always knew how to encourage and support young scientists. Tonight, the Gérard Siest award is an important recognition which augurs a bright future to the first recipient Dr. Jean-Baptiste WOILLARD (France).

L-R: Prof. Maurizio Ferrari, Chair Awards committee; Prof. Tomas Zima, IFCC Awards committee; Prof. Khosrow Adeli, IFCC President; Dr. Jean Baptiste Woillard, Gérard Siest Award recipient

Article continued on next page

Jean-Baptiste Woillard is Doctor of Pharmacy since 2008. He obtained a Master in Pharmacology in 2007 followed by a PhD in Pharmacogenetics and Pharmacokinetics in 2011. He is currently an Associate Professor of Medical Pharmacology at the Faculty of Medicine of Limoges and is Head of the "TDM and pharmacokinetics" unit in the Department of Pharmacology, Toxicology and Pharmacovigilance (managed by Prof. Pierre Marquet) at Limoges University Hospital. He is a member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and chair of the Pharmacometrics Committee, the European Association for Clinical Pharmacology and Therapeutics (EACPT) and of the French Society of Pharmacology and Therapeutics (SFPT). Dr Woillard conducts his research in the INSERM U1248 unit Pharmacology & Transplantation (INSERM is the French National Institute of Medical and Health Research) on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: pharmacogenetic and pharmacodynamic studies of IS; development of original models in pharmacokinetics; statistical modeling; and application to routine treatment personalization in transplant recipients. He is also interested in antibiotics modeling and their dose individualization. His new research focused on the application of machine learning methods to therapeutic drug monitoring and pharmacometrics. He has 87 publications in peer-reviewed, international journals, he has done over 28 presentations in national and international congresses and has been invited to give 13 academic or IVD companies plenary lectures. He is member of the SFBC (Société Française de Biologie Clinique).

Many thanks to the award committee chaired by Prof. Maurizio Ferrari for having selected an outstanding young researcher. Congratulations to Prof. Khosrow Adeli, IFCC President and to all the IFCC family for the amazing awards ceremony and great IFCC-APFCB Seoul Congress 2022!

News from the IFCC Website

IFCC Calls for nominations

Prof. Khosrow Adeli, President of IFCC, and of Prof. Päivi Laitinen, Chair of IFCC Congresses and Conferences Committee, are announcing a call for nominations for **one Full Member position within the IFCC Congresses and Conferences Committee**.

Replies should be sent to the IFCC Office (cardinale@ifcc.org) by **21 October 2022**.

Prof. Nader Rifai, Chair of IFCC Education and Management Division, is announcing a call for nominations for **three Full Member positions within the Committee on Clinical Applications of Cardiac Bio-Markers (C-CB)**.

Replies should be sent to the IFCC Office (cardinale@ifcc.org) by 15 November 2022.

For any further information on nominations, please refer to your National or Corporate Representative.

Information and contacts are available here.

EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

News from EFLM task groups

EFLM Task Group "European Lab Day" - save the date!

reported by Tara Rolić
Chair, EFLM TG "European Lab Day"

November 5th is a special day for European Laboratory Specialists. With great pleasure, EFLM announces the first **European Lab Day**! Together, we can make our profession visible and recognizable by opening doors of our laboratories and showing what we do. Interested, but not sure how to participate?

Follow EFLM on social media and in web page - find ideas. It is important to show we are **#morethananumber**.

EFLM Task Group „Chronic Kidney Disease" survey

reported by Tara Rolić
Member, EFLM WG "Promotion and Publications"

Task Group on Chronic Kidney Disease has considered important to update and evaluate the evolution of laboratory medicine on the state of the art of creatinine, cystatin C and measurement of the glomerular filtration and prepared a survey to increase the quality of the paper which will be developed by the TG.

In 2019, an EFLM survey on the state of the art of creatinine, cystatin C and measurement of the glomerular filtration rate was performed and obtained a large number of replies.



The results were highly interesting, but many participants were in transition from a formula to the other, they wanted to change the measurement of creatinine, implement cystatin C, or start measuring iohexol. In addition, there have been some recent changes, like the "race-free" CKD-EPI equation to estimate GFR.

Therefore, the EFLM Task Group on Chronic Kidney Disease has considered important to update and evaluate the evolution of laboratory medicine on these tests over a 3 years period preparing this new survey. This survey will be useful also to increase the quality of the paper which will developed by the EFLM TG-CKD.

The TG-CKD kindly asks you to fill in the survey by **October 15**, 2022 and thanks in advance for your time and contribution to this work!

News from the IFCC Website

DiV – Número Octubre 2022

DIAGNÓSTICO *IN VITRO*

Lee todas las novedades y noticias, los artículos científicos, la carta al director, la sección dedicada a los jóvenes científicos IFCC y no olvides la entrevista “El Microscopio”. In this issue, the IFCC WG-IANT confirms its commitment to advance excellence in laboratory medicine for better healthcare worldwide in Latin America.

Click here to access the PDF version

Clic aquí para acceder la versión PDF

Click here to access the Flip version

Clic aquí para acceder la versión Flip

IFCC'S CALENDAR OF CONGRESSES, CONFERENCES & EVENTS

Calendar of IFCC Congresses/Conferences and Regional Federations' Congresses

Oct 19, 2022		*From Data to Decisions: Data and Analytics Leadership in Clinical Laboratory Management*	Live webinar
Nov 9, 2022		*Single Cell and Spatial Transcriptomics: clinical application*	Live webinar
Nov 23, 2022		*The role of key laboratory tests in the investigation and management of metabolic bone disease*	Live webinar
Dec 7, 2022		*Challenges in implementing Pharmacogenetics in routine Clinical Practice*	Live webinar
May 21 - 25, 2023		*XXV IFCC - EFLM WorldLab EuroMedLab - Rome 2023*	Rome, IT
May 26 -30, 2024		*XXVI IFCC WORLDLAB - Dubai 2024*	Dubai, UAE

Calendar continued on next page

April 2024		*XXVI COLABIOCLI 2024*	Cartagena, CO
October 31 - Nov 3, 2024		*APFCB 2024 Sydney*	Sidney, AU
2025 *Date TBA*		*XXVI IFCC-EFLM EUROMEDLAB 2025*	*Venue* *to be selected*
2026 *Date TBA*		*XXVII IFCC WORLDLAB 2026*	*Venue* *to be selected*
2027 *Date TBA*		*XXVII IFCC-EFLM EUROMEDLAB 2027*	*Venue* *to be selected*
2028 *Date TBA*		*XXVIII IFCC WORLDLAB 2028*	*Venue* *to be selected*
2029 *Date TBA*		*XXVIII IFCC-EFLM EUROMEDLAB 2029*	*Venue* *to be selected*

Calendar continued on next page

2030 *Date TBA*		*XXIX IFCC WORLDLAB 2030*	*Venue* *to be selected*

Other events with IFCC auspices

Aug 1, 2022 - Apr 30, 2023	*5th International program in control of analytical quality in the clinical laboratory*	Quality Academics, online event
Oct 13 - 17, 2022	*46th ISOBM Congress*	Bled, SI
Oct 17 - 19, 2022	*7th SIPMeL National Congress Laboratory Medicine: New Complexities and Future Strategies*	Hybrid event Riva del Garda, IT
Oct 18 - 20, 2022	*AACB 59th Annual Scientific Conference*	Hybrid event, Perth, AU
Oct 26 - Nov 15, 2022	*How to write and publish: a good scientific & professional article*	Online event
Oct 26 - 30, 2022	*TBS International Biochemistry Congress 2022 & 33rd National Biochemistry Congress organized by the Turkish Biochemical Society*	Izmir, TR
Oct 28, 2022	*International Conference on Immunoassay*	Snibe Brussels, BE
Nov 7 - 9, 2022	*XI Argentine Congress of Quality in the Clinical Laboratory (CALILAB2022)*	Mar del Plata City, AR
Nov 11 - 14, 2022	*20th International Congress National College of Bacteriology*	Bucaramanga, CO
Nov 18, 2022	*Annual Meeting of the RBSLM*	Brussels, BE

Calendar continued on next page

Nov 19, 2022	*Inter-QC Topics: Measurement uncertainty and its usefulness in the laboratory*	Quality Academics, online event
Nov 25 - 26, 2022	*Chem Con 2022 - 'Metabolomics: Revolutionizing Clinical Chemistry' - PSCP Annual Congress*	Karachi, PK
Nov 30, 2022	*14th International Scientific Meeting: Implementation of metrological traceability in laboratory medicine: where we are and what is missing*	Sesto San Giovanni Milan, IT
Dec 1, 2022	*Developments in reference measurement systems for C-reactive protein and the importance of maintaining currently used clinical decision-making criteria - JCTLM in cooperation with CIRME*	Sesto San Giovanni Milan, IT
Dec 1 - 2, 2022	*Journées de l'innovation en biologie (JIB 2022)*	Hybrid event, Paris, FR
Dec 6 - 8, 2022	*4th International Meeting in Clinical Chemistry & Laboratory Medicine & SSCC 8th Annual Meeting*	Hybrid event, Riyadh, SA
Jan 1 - Jul 31, 2023	*Inter-QC Topics*	Quality Academics, online event
Feb 9 - 10, 2023	*Labquality Days 2023*	Helsinki, FI
Feb 15 - 18, 2023	*The International Laboratory Diagnostics Congress*	Online event

IFCC Executive Board 2021-2023

Khosrow ADELI
President

David KINNIBURGH
Secretary

Alexander HALIASSOS
Treasurer



Joseph PASSARELLI
Corporate Representative

Regional Representatives

AB OKESINA
African Federation of Clinical Chemistry (**AFCC**)

A. HEDHILI
Arab Federation of Clinical Biology (**AFCB**)

S. SETHI
Asia-Pacific Fed for Clin Biochem and Lab Med (**APFCB**)

T. OZBEN
European Fed of Clin Chem and Lab Medicine (**EFLM**)

A.M. LENA
Latin-American Confederation of Clin Biochemistry (**COLABIOCLI**)

S. HILL
North American Fed of Clin Chem and Lab Med (**NAFCC**)

IFCC Divisions and C-CC Chairs

P. GILLERY (FR)
Scientific Division Chair

N. RIFAI (US)
Education and Management Division Chair

T. PILLAY (ZA)
Communications and Publications Division Chair

S. BERNARDINI (IT)
Emerging Technologies Division Chair

P. LAITINEN (FI)
Congresses and Conferences Committee Chair

IFCC Office Staff

(L-R) Silvia Cardinale, Paola Bramati, Silvia Colli Lanzi, Sofia Giardina, Smeralda Skenderaj

IFCC MEMBERSHIP

Full Members

Albania (AL)
Algeria (DZ)
Argentina (AR)
Australia and New Zealand (AU/NZ)
Austria (AT)
Belgium (BE)
Bolivia (BO)
Bosnia Herzegovina (BA)
Brazil (BR)
Bulgaria (BG)
Canada (CA)
Chile (CL)
China (Beijing) (CN)
China (Taipei) (TW)
Colombia (CO)
Croatia (HR)
Cuba (CU)
Cyprus (CY)
Czech Republic (CZ)
Denmark (DK)
Dominican Republic (DO)
Ecuador (EC)
Egypt (EG)
Estonia (EE)
Ethiopia (ET)
Finland (FI)
France (FR)
Georgia (GE)
Germany (DE)
Greece (GR)
Guatemala (GT)
Hong Kong (HK)
Hungary (HU)
Iceland (IS)
India (IN)
Indonesia (ID)
Iran (IR)
Iraq (IQ)
Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)
Jordan (JO)
Kazakhstan (KZ)
Kenya (KE)
Korea (KR)
Kosovo (XK)
Latvia (LV)
Lebanon (LB)
Libya (LY)
Lithuania (LT)
Luxembourg (LU)
Malawi (MW)
Malaysia (MY)
Mexico (MX)
Montenegro (ME)
Morocco (MA)
Myanmar (MM)
Nepal (NP)
Netherlands (NL)
Nigeria (NG)
North Macedonia (MK)
Norway (NO)
Pakistan (PK)
Palestine (PS)
Panama (PA)
Paraguay (PY)
Peru (PE)
Philippines (PH)
Poland (PL)
Portugal (PT)
Romania (RO)
Russia (RU)
Saudi Arabia (SA)
Serbia (SRB)
Singapore (SG)
Slovak Republic (SK)
Slovenia (SI)
South Africa (ZA)
Spain (ES)
Sri Lanka (LK)
Sudan (SD)
Sweden (SE)
Switzerland (CH)
Syrian Arab Republic (SY)
Thailand (TH)
Tunisia (TN)
Turkey (TR)
Ukraine (UA)
United Kingdom (UK)
United States (US)
Uruguay (UY)
Vietnam (VN)
Zambia (ZM)
Zimbabwe (ZW)

Regional Federations

Arab Federation of Clinical Biology (AFCB)
African Federation of Clinical Chemistry (AFCC)
Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)
European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Latin America Confederation of Clinical Biochemistry (COLABIOCLI)
North American Federation of Clinical Chemistry and Laboratory Medicine (NAFCC)



Corporate Members

Abbott
Agappe Diagnostics, Ltd.
Arkray, Inc.
Asahi Kasei Pharma Corp.
Autobio Diagnostics Co., Ltd.
BD Life Sciences – Preanalytical Systems
Beckman Coulter, Inc.
The Binding Site Group, Ltd.
Biomasterclin Laboratorios Venezuela
Bio-Rad Laboratories
C.P.M. Diagnostic Research, SAS
Diagnostica Stago
DiaSorin
DiaSys Diagnostic Systems GmbH
ET Healthcare Inc.
Fujifilm Wako Pure Chemical Corporation
Fujirebio Europe
GenScript Biotech Corporation
Gentian, AS
Helena Biosciencies Europe
Hemas Hospitals (PVT) Ltd.
HyTest, Ltd.
Immunodiagnostic Systems - IDS
Instrumentation Laboratory
Jangsu BioPerfectus Co., Ltd.
Labtronic
LumiraDx
Maccura Biotechnology Co., Ltd.
MedicalSystem Biotechnology Co., Ltd.
Medix Biochemica
Megalab, JSC
A. Menarini Diagnostics
Mindray - Shenzhen Mindray Bio-Medical
Nittobo Medical Co., LTD.
Nova Biomedical Corporation
Oneworld Accuracy Collaboration
Ortho-Clinical Diagnostics, Inc.
PerkinElmer
PHC Europe B.V.
Quality Academics S.C.
Radiometer Medical ApS
Randox Laboratories, Ltd.
Roche Diagnostics
Sansure Biotech Inc.
Sebia S.A.
Sekisui Diagnostics Ltd.
Sentinel CH SpA
Shanghai Kehua Bio-Engineering Co., Ltd.
Shanghai Zhicheng Biol. Tech. Co., Ltd.
Shenzhen YHLO Biotech Co., Ltd
Siemens Healthcare Diagnostics
Snibe Co., Ltd.
Synlab
Sysmex Europe, GmbH
Technogenetics
Thermo Fisher Scientific
Tosoh Corporation
Labor Dr. Wisplinghoff
Wuhan Life Origin Biotech Joint Stock Co., Ltd.

Affiliate Members

Botswana: Institute of Clinical Laboratory Professionals
Brazil: Sociedade Brasileira de Patologia Clínica / Medicina Laboratorial (SBPC/ML)
China: Lab Medicine Committee, China Association of Medical Equipment (LMC)
Egypt: Egyptian Association of Healthcare Quality and Patient Safety
France: French National Network of Accredited Laboratories of Medical Biology (LABAC)
India: Association of Medical Biochemists of India (AMBI)
Iran: Iranian Association of Clinical Laboratory Doctors (IACLD)
Jordan: Society for Medical Technology & Laboratories (SMTL)
Kazakhstan: Public Association - Federation of Laboratory Medicine (FLM)
Mexico: Federación Nacional de Químicos Clínicos (CONAQUIC A.C.)
Nepal: Nepalese Association for Clinical Chemistry (NACC)
Philippines: Philippine Council for Quality Assurance in Clinical Laboratories (PCQACL)
Romania: Order of the Biochemists, Biologists, Chemists in Romanian Health System (OBBCSSR)
Serbia: Serbian Society for Clinical Laboratory Medicine and Science (SCLM)
Spain: Andalusian Society for Clinical Analysis and Laboratory Medicine (SANAC)
Asociación Española de Biopatología Médica - Medicina de Laboratorio (AEBM-ML)
Asociación Española de Farmacéuticos Analistas (AEFA)
Sri Lanka: College of Chemical Pathologists of Sri Lanka (CCPSL)
Turkey: Society of Clinical Biochemistry Specialists (KBUD)
Ukraine: Association for Quality Assurance of Laboratory Medicine (AQALM)
United Arab Emirates: Genetic Diseases Association (UAEGDA)

Publisher

Communications and Publications Division (CPD) of the IFCC

The Communications and Publications Division publishes ten editions of the e-News per year, including two double issues.

Editor

Katherina Psarra, MSc, PhD
Department of Immunology - Histocompatibility
Evangelismos Hospital, Athens, Greece
E-mail: enews@ifcc.org

Design & Production:

Insoft Digital

Circulation

The eNews is distributed to all IFCC members registered on-line to receive it and to all IFCC sponsors.

Deadlines for submissions to the eNews

N° 1/2 – January/February: by mid January

N° 3 – March: by mid February

N° 4 – April: by mid March

N° 5 – May: by mid April

N° 6 – June: by mid May

N° 7/8 – July/August: by mid June

N° 9 – September: by mid August

N° 10 – October: by mid September

N° 11 – November: by mid October

N° 12 – December: by mid November

If you want to submit an article or advertisement to be published in the eNews, send it to:
Katherina Psarra, Editor, IFCC eNews
E-mail: enews@ifcc.org